Update: Broadening hypoxia focus with TH-4000
Preclinical and Phase I data on Threshold’s newest hypoxia asset TH-4000 were recently presented at AACR. Threshold now plans to move TH-4000 into Phase II trials in both lung and head and neck cancers. At this stage we do not formally include TH-4000 in our unchanged $949m valuation, although TH-4000 could address sizeable markets with often limited treatment options. The major catalysts for Threshold remain related to evofosfamide, where the number of events needed for analysis of the Phase III STS and pancreatic trials should be reached in H215.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.